NetraMark
Luca Pani is a distinguished professional in the fields of pharmacology and clinical pharmacology, currently serving as Chief Innovation and Regulatory Officer at NetraMark since July 2022 and Chief Advisor at Relmada Therapeutics, Inc. since September 2021. Pani holds academic positions as a Professor at both Università degli Studi di Modena e Reggio Emilia and the University of Miami, Miller School of Medicine. Pani previously excelled as Chief Scientific Officer at Edra S.p.A. and held leadership roles at WCG VeraSci and the National Research Council of Italy, among others, including significant contributions at the European Medicines Agency and as Director General of AIFA Agenzia Italiana del farmaco. Pani's educational background includes advanced training in neuropharmacology and molecular biology, as well as a medical degree from Università degli Studi di Cagliari.
This person is not in any teams
This person is not in any offices
NetraMark
NetraMark combines proprietary QML/ML algorithms with cross-domain expertise to bring ML commercialization into reality, starting with the pharmaceutical space in drug development where we utilize large and small data in order to help pharmaceutical companies understand their patient populations better. Our technology allows for the utilization of phase II data in order to optimize phase III trials from the vantage of their specific patient population.